Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $185.50 Average PT from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given an average rating of “Hold” by the five brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $185.50.

A number of research firms have commented on ATRA. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research note on Wednesday, June 26th. They set a “hold” rating for the company. The Goldman Sachs Group reduced their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research report on Wednesday, July 17th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their price objective for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. Canaccord Genuity Group restated a “buy” rating and issued a $13.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st.

Atara Biotherapeutics Stock Performance

NASDAQ ATRA opened at $9.47 on Wednesday. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $49.00. The business’s fifty day moving average is $8.66 and its two-hundred day moving average is $13.26. The stock has a market capitalization of $45.62 million, a P/E ratio of -0.18 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The company had revenue of $28.64 million during the quarter, compared to analyst estimates of $48.30 million. On average, research analysts forecast that Atara Biotherapeutics will post -12.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ATRA. Price T Rowe Associates Inc. MD grew its holdings in shares of Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after acquiring an additional 4,903,159 shares in the last quarter. Acadian Asset Management LLC grew its stake in Atara Biotherapeutics by 49.5% in the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after purchasing an additional 873,133 shares in the last quarter. Redmile Group LLC grew its stake in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after purchasing an additional 156,863 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares in the last quarter. Finally, Delap Wealth Advisory LLC purchased a new stake in shares of Atara Biotherapeutics during the 1st quarter worth about $29,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.